We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Powered Whole-Slide Image Analyzer Predicts Immunotherapy Response for Rare Cancer Patients

By LabMedica International staff writers
Posted on 13 Nov 2024
Print article
Image: SCOPE IO has shown promise in predicting immunotherapy response in rare cancer patients (Photo courtesy of Lunit)
Image: SCOPE IO has shown promise in predicting immunotherapy response in rare cancer patients (Photo courtesy of Lunit)

Immunotherapy, especially immune checkpoint inhibitors like pembrolizumab, has become a groundbreaking treatment for cancer patients. However, not all patients respond the same way to this therapy, and identifying who will benefit the most remains a challenge, particularly in the case of rare tumor types where treatment options and research data are sparse. Now, a new study has highlighted the potential of using artificial intelligence (AI) to assess the tumor microenvironment to predict treatment responses in patients with rare cancers receiving pembrolizumab.

In the study, researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) utilized Lunit’s (Seoul, South Korea) AI-powered whole-slide image analyzer, Lunit SCOPE IO, to examine tumor microenvironment characteristics in biopsies taken both before and during treatment from patients with rare tumors undergoing pembrolizumab therapy. The study involved the analysis of over 500 slides from more than 10 different rare tumor types. The results suggest that Lunit SCOPE IO can effectively detect specific patterns in tumor samples that are linked to more favorable treatment outcomes. Patients whose tumors exhibited AI-detected changes in intratumoral immune cells (tumor-infiltrating lymphocytes; iTIL) and tumor content were significantly more likely to show positive responses to immunotherapy. These groundbreaking research findings reveal the potential of AI to predict how well patients with rare cancers will respond to immunotherapy treatments.

"These findings highlight how our AI technology can provide deep insights into the unique and challenging tumor microenvironment seen in rare cancers, and represent a critical advancement in our understanding of rare tumor biology," said Brandon Suh, CEO of Lunit. "This study has demonstrated the value of Lunit SCOPE IO in an important clinical setting, showcasing its potential to personalize treatment for patients who have limited therapeutic options. We believe these advancements are a testament to the transformative impact AI can have on oncology and patient outcomes."

Related Links:
Lunit
The University of Texas MD Anderson Cancer Center

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Centrifuge
Centrifuge 5430/ 5430 R
New
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0

Print article

Channels

Hematology

view channel
Image: Personalized blood count could lead to early intervention for common diseases (Photo courtesy of 123RF)

Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals

A complete blood count (CBC) screening is a standard examination most physicians request for healthy adults. This test is essential for evaluating a patient’s overall health with a single blood sample.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The BIOFIRE® FILMARRAY® Tropical Fever Panel has received U.S. FDA Special 510(k) clearance (Photo courtesy of bioMérieux)

Syndromic PCR Test Rapidly and Accurately Identifies Pathogens in Patients with Tropical Fever Infections

Tropical fevers refer to infections that are common in, or unique to, tropical and subtropical regions. As these diseases spread to previously unaffected areas and can be brought in by travelers, infections... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.